transmembrane and coiled-coil domain family 3Genealiases: []
Q-omics provides the consensus-scored TMCC3 profile across patient tissues and cancer cell-line models. TMCC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMCC3 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, TMCC3 protein abundance shows 22,505 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where TMCC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMCC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMCC3 survival associations across molecular data types. TMCC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMCC3 RNA expression–survival associations across cancer types. High TMCC3 expression shows unfavorable associations in ACC, but favorable associations in KIRC, UCS, ESCA, CHOL and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMCC3 RNA expression.
This table summarizes TMCC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMCC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMCC3 shows lower tumor expression in COAD, BLCA and LUAD and higher tumor expression in HNSC, KIRC and LIHC. The COAD box plot shows higher TMCC3 RNA expression in normal versus tumor tissue (log2 FC = −2.330, t-test p < 0.001).
This table shows molecular features associated with TMCC3 in patient tissues and cancer cell lines. In patient samples, TMCC3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMCC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
